P401 Tofacitinib tissue exposure correlates with endoscopic outcome

Bram Verstockt(Universitair Ziekenhuis Leuven), Séverine Vermeire(KU Leuven), Jeffrey A. Smith(Nova Scotia Health Authority), Marc Ferrante(Universitair Ziekenhuis Leuven), Dahham Alsoud(KU Leuven), Geert D’Haens(Amsterdam University Medical Centers), P Rahimian(Progenity (United States)), J. van Oostrom(Amsterdam University Medical Centers), João Sabino(KU Leuven), Jack Stylli(Georgetown University), Sharat Singh(Mirati Therapeutics (United States)), Sara van Gennep(Amsterdam Neuroscience)
Journal of Crohn s and Colitis
January 1, 2022
10.1093/ecco-jcc/jjab232.528
Cited by 5

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k